NCT04684602 · Phase 1 · RECRUITING
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
This Phase 1 trial is testing whether mesenchymal stem cell therapy — delivered as products called PrimePro and PrimeMSK — is safe and tolerable across a wide range of chronic and acute conditions, including neurological ones. Phase 1 means the primary goal is checking safety in humans, not proving the treatment works. The trial covers an unusually broad list of conditions, which makes it hard to evaluate any single use case closely.
You may qualify if
- Age 18 and older
- Ability to provide informed consent
- Availability for follow up visits
You're excluded if
- Active or recent malignancy (within last 2 years)
- Pregnancy or breast-feeding
- Inability to provide informed consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2022-04-29